Metraipolis › archive › dc_37fa3d41cd30

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world… — Europe PMC PMID:42120657

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42120657
DOI: 10.1007/s00277-[numero omesso]-8
License (as archived): solo-consultazione
Archived: 2026-11-02T09:55:10.804Z
SHA-256 of the archived text: 460160aca2405ab560500b05871b9bb4092c56e62f4a1ef809aa601a1bc1cec4
Stable URL of this page: https://metraipolis.com/documento/dc_37fa3d41cd30

How to cite

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world… — Europe PMC PMID:42120657 — Europe PMC (en), https://europepmc.org/article/MED/42120657 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_37fa3d41cd30 (Metraipolis archive dc_37fa3d41cd30, sha256 460160aca2405ab560500b05871b9bb4092c56e62f4a1ef809aa601a1bc1cec4)

BibTeX

@misc{dc37fa3d41cd30,
  title = {Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world… — Europe PMC PMID:42120657},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42120657},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_37fa3d41cd30; sha256 460160aca2405ab560500b05871b9bb4092c56e62f4a1ef809aa601a1bc1cec4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42120657. Agents can read the archived copy with the MCP tool read_document.